Edwards scraps AAA program
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' inability to find a buyer for its LifePath aortic aneurysm endovascular graft system will lead to termination of the program, the company says. The only firms with endovascular surgery sales forces capable of supporting LifePath already offer AAA grafts or are developing them, Edwards explains. The company announced its intention to exit the AAA business in December (1"The Gray Sheet" Dec. 15, 2003, p. 7). European sales will end in June. Edwards says it will complete patient follow-up for a U.S. study which closed enrollment in January...
You may also be interested in...
Selling AAA in Europe
Edwards Lifesciences will distribute Endologix' PowerLink abdominal aortic aneurysm stent graft in Belgium, France, Germany and the UK. PowerLink received CE mark in 1999. A PMA is pending at FDA, and the firm expects approval during the second half of the year. Endologix plans to create a direct sales force for U.S. commercialization. Edwards recently abandoned its LifePath AAA program after unsuccessfully seeking a buyer (1"The Gray Sheet" April 12, 2004, In Brief)...
Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer
Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”